<DOC>
	<DOC>NCT00518622</DOC>
	<brief_summary>The purpose of this study is to investigate the effectiveness, safety, and tolerability of MK7009 in patients infected with Hepatitis C</brief_summary>
	<brief_title>Study the Safety and Effectiveness of MK7009 in Hepatitis C Infected Patients (MK-7009-004)(COMPLETED)</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<criteria>Subject is a man or a woman aged 18 to 55 years of age. Subject has chronic Hepatitis C Subject is willing to not use alcohol for 2 weeks prior to therapy and through the study followup period Patient has evidence of advanced liver disease. Patient has human immunodeficiency virus (HIV) Patient has Hepatitis B</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>August 2015</verification_date>
</DOC>